---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003216"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:53:09.755053+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aligos Q1 net loss $35.6M (-$0.84/sh); HBV STOPS/ASO programs terminated; cash $183.2M

## Summary
- Net loss of $35.6M ($0.84 per share) vs $27.7M ($0.74) in Q1 2021; R&D expense rose to $31.7M.
- Cash, equivalents and marketable securities $183.2M at March 31, 2022; runway into first half 2024.
- Terminated STOPS and ASO HBV programs in Q1 due to insufficient antiviral activity and poor tolerability.
- ALG-000184 (HBV CAM) 28-day top-line data expected Q2 2022; 12-week cohort initiating Q3.
- COVID PI candidate ALG-097558 7-20x more potent than nirmatrelvir vs variants; Phase 1 CTA planned H2 2022.

## SEC filing metadata
- accession: 0001171843-22-003216
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184322003216/0001171843-22-003216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184322003216/f8k_050422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003216
- JSON: https://secwatch.observer/filing/0001171843-22-003216.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.